Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Epizyme, Inc. - Common Stock (NQ:EPZM)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Epizyme, Inc. - Common Stock

< Previous 1 2 Next >
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
From Kahn Swick & Foti, LLC
Via Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
From Kahn Swick & Foti, LLC
Via Business Wire
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Ipsen to acquire Epizyme, expanding its portfolio in oncology
From Epizyme, Inc.
Via Business Wire
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
From Epizyme, Inc.
Via Business Wire
Epizyme To Participate in H.C. Wainwright Global Investment Conference
From Epizyme, Inc.
Via Business Wire
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Date of First Quarter 2022 Financial Results
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Pricing of Public Offering of Common Stock
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Proposed Public Offering of Common Stock
From Epizyme, Inc.
Via Business Wire
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
From Epizyme, Inc.
Via Business Wire
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
From Epizyme, Inc.
Via Business Wire
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
From Epizyme, Inc.
Via Business Wire
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Updates to Its Board of Directors
From Epizyme, Inc.
Via Business Wire
Epizyme to Participate in Jefferies London Healthcare Conference
From Epizyme, Inc.
Via Business Wire
Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Date of Third Quarter 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Epizyme Announces CEO Succession
From Epizyme, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.